Mutations in the juxtamembrane segment of the cholesterol-binding site of APP alter its processing and promotes production of shorter, less toxic A β peptides.

Linda Hanbouch^{a,*}, Béatrice Schaack^{b,c,*}, Amal Kasri^{a,*}, Gaëlle Fontaine^{a,*}, Eleni Gkanatsiou^d, Gunnar Brinkmalm^d, Erik Portelius^{d,e}, Kaj Blennow^{d,e}, Gilles Mourier^f, Nicolas Gilles^f, Mark J Millan^g, Catherine Marquer^a, Henrik Zetterberg^{d,e,h,i}, Lydie Boussicault^{a,*} and Marie-Claude Potier^{a,*}.

^a Institut du Cerveau et de la Moelle, ICM, CNRS UMR7225 - INSERM U1127 – UPMC Hôpital de la Pitié-Salpêtrière 47 Bd de l'Hôpital 75013 Paris

^b Univ. Grenoble Alpes, CNRS, INP, TheRex Team, TIMC-IMAG, F-38700 La Tronche, France.

^c Univ. Grenoble Alpes, CEA, CNRS, IBS, F-38044 Grenoble, France.

^d Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, S-431 80 Mölndal, Sweden.

^e Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, S-431 80 Mölndal, Sweden

^f Université Paris Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SIMoS, 91191 Gif-sur-Yvette, France

Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, S-431 80 Mölndal, Sweden

^g CTI-Neuropsychiatry, IDR Servier, 125 chemin de ronde, 78290 Croissy-sur-Seine, France

^h Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG United Kingdom

ⁱ UK Dementia Research Institute at UCL, London WC1E 6BT, United Kingdom

* These authors contributed equally to the work.

Corresponding author: Marie-Claude Potier, PharmD, PhD

marie-claude.potier@upmc.fr

Abstract

Background: The brains of patients with Alzheimer's disease (AD) reveal increased cellular membrane levels of cholesterol. Correspondingly, we previously showed that elevating levels of membrane cholesterol in neuronal cultures recapitulates early AD phenotypes including excessive cleavage of amyloid β (A β) peptides from the amyloid precursor protein (APP). Here we aimed to evaluate how the presence of a cholesterol-binding site (CBS) in the transmembrane and juxtamembrane regions of APP regulates its processing.

Methods: We generated seven single and two double APP mutants at amino acid positions 22, 26, 28, 29, 33, 39 of the A β sequence changing the charge and/or hydrophobicity of the targeted amino acids. HEK293T cells were transfected with APP constructs and secreted A β peptides were measured using ELISA and mass spectrometry (MS). APP processing in normal and high cholesterol condition, and endocytosis were assessed in stably expressing APP^{WT} and APP^{K28A} HEK293T clones. Finally, we measured the binding of synthetic peptides derived from the A β sequence to cholesterol-rich exosomes purified from control HEK293T cells.

Results: Most mutations triggered a reduction in the production of A β 40 and A β 42 peptides, whereas only juxtamembrane mutants resulted in the generation of shorter A β peptides. We confirmed by mass spectrometry this specific change in the profile of secreted A β peptides for the most characteristic APP^{K28A} mutant. A transient increase of plasma membrane cholesterol enhanced the production of A β 40 by APP^{WT}, an effect absent with APP^{K28A}. The enzymatic activity of α -, β - and γ -secretases remained unchanged in cells expressing APP^{K28A}. Similarly, APP^{K28A} subcellular localization in early endosomes did not differ to APP^{WT}. Finally, WT but not CBS mutant A β derived peptides bound to cholesterol-rich exosomes.

Conclusions: Taken together, these data reveal a major role of the juxtamembrane region of APP in binding to cholesterol and accordingly in the regulation of APP processing. Binding of cholesterol to K28 could staple APP to the juxtamembrane region thereby permitting access to γ -secretase cleavage at positions 40-42. The APP^{K28A} mutant would lie deeper in the membrane, facilitating the production of shorter A β peptides and unveiling this specific region as a novel target for reducing the production of toxic A β species.

Keywords: Alzheimer's disease, cholesterol, Amyloid Precursor Protein, A β , mutant.

Background

Alzheimer's disease (AD) is the most common form of dementia in the elderly population and is characterized by two prominent pathologies, extracellular amyloid- β (A β) containing plaques and intraneuronal fibrillary tangles comprised of aberrantly hyperphosphorylated tau protein (1). A β peptides of various lengths are produced by sequential proteolysis of the transmembrane Amyloid Precursor Protein (APP) by the β -secretase BACE1 and the γ -secretase which operate in the membrane bilayer (2). Amyloidogenic APP processing occurs in the endolysosomal compartment following clathrin-dependent APP internalization (3).

There is considerable interest in endogenous factors controlling the processing of APP and their potential therapeutic modulation. One line of research has focused on cholesterol, which is produced in the brain (independently of the periphery) by astrocytes, then shuttled to neurons bound to apolipoprotein E (APOE) protein. APOE encoded by the polymorphic gene *APOE* which possesses three alleles ϵ 2, ϵ 3 and ϵ 4 (4), with the strongest genetic risk factor for sporadic AD being the ϵ 4 allele of *APOE* (5). Levels of cholesterol are elevated in the brain of people diagnosed with AD and it is known to accumulate in amyloid plaques (6-10). Additionally, APP processing occurs preferentially in cholesterol-enriched domains of the plasma membrane named lipid rafts (11, 12). We previously showed that an increase of cholesterol in the plasma membrane triggers relocalization of APP-BACE1 complexes in lipid rafts and their clathrin-dependent internalization in enlarged endosomes, leading to increased APP processing and secretion of A β 40 and A β 42 (13-16). Cholesterol has been also described as a positive regulator of BACE1 and γ -secretase the enzyme cleaving the β C-terminal fragment (β CTF) resulting from the processing of APP by BACE1 (17, 18). Reciprocally, APP regulates cholesterol homeostasis by transcriptional regulation of key cholesterol synthesis enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (19).

Molecular simulation and physicochemical characterization showed that the A β 5–16 segment binds to the ganglioside GM1, while the A β 22–35 segment is linked to cholesterol in the bilayer, directing the partial insertion of the peptide in the lipid raft (20, 21). In addition, structural studies using nuclear magnetic resonance identified a cholesterol-binding site (CBS) in the transmembrane segment forming a flexible curved α -helix and in the juxtamembrane domain of the β CTF (22-24) (Fig. 1). Molecular dynamic simulations found that the APP transmembrane region and particularly the GxxxG dimerization motif was not sufficient for binding to membrane cholesterol, which also required the APP juxtamembrane segment (25). Two helical secondary structures in the β CTF fragment of APP were identified in lysophospholipid micelles (23). An R-helix that includes the transmembrane domain (TMD) extends from N698 to L723 in the sequence of APP⁷⁷⁰ and is terminated by three consecutive lysines. A second short R-helical segment (F690 through E693 in APP⁷⁷⁰ and F19 through E22 in the A β sequence) is located in the extracellular domain between the site of α -secretase cleavage (after K687 in APP⁷⁷⁰ and K16 in A β) and the start of the TMD. This second domain is a short reentrance loop located in a juxtamembrane region.

To clarify how this CBS regulates APP processing, we produced seven single mutants in the APP⁷⁵¹ protein either in the juxta-membrane region at positions 22, 26 and 28 or in the TMD at positions 29, 33 and 39 of the A β sequence (positions 673, 677 and 679, and positions 680, 684 and 690 of APP⁷⁵¹). In addition, two double mutants, 26/28 and 29/33, were constructed. We show that juxta-membrane mutants generate shorter A β peptides. We further demonstrate that the amount of A β peptides produced by one of the CBS mutants (K28A) is insensitive to the level of plasma membrane cholesterol, in distinction to APP^{WT} (13, 16). Since shorter A β sequences are known to be less aggregation-prone and toxic than the A β 40 and A β 42 peptides found in amyloid deposits (26, 27), targeting the juxta-membrane CBS-containing region of APP could be a new therapeutic option for inhibiting cholesterol-binding and hence reducing the production of toxic A β species.

Methods

Plasmid and reagents

The APP⁷⁵¹ plasmid was a kind gift from Dr. Frederic Checler (IPMC, Valbonne, France). The APP-mCherry plasmid was generated by introducing the APP⁷⁵¹ sequence in the pmCherry-N1 vector (Clontech) at the *XmaI/AgeI* restriction site. M β CD-cholesterol complex, bovine serum albumin (BSA), sucrose and poly-L-lysine were purchased from Sigma-Aldrich. The antibody directed against EEA1 (Early Endosome Antigen 1) was from Cell Signaling Technology. Goat anti rabbit IgG coupled to Alexa568 was from Life Technologies.

Peptides synthesis

Amyloid peptides derived from the A β sequence (position 15 to 33) with an additional hydrophobic sequence (YEVH) linked to biotin were synthesized. Fmoc-amino acids, and 2-(6-chloro-1H-benzotriazole-1-yl)-1, 1, 3, 3-tetra-methylaminium hexafluorophosphate (HCTU) were obtained from Novabiochem. N-biotine-NH(PEG)X-COOH were purchased at Merck and Sigma Aldrich. The resin and all the peptide synthesis grade reagents (N-methylpyrrolidone (NMP), N-methylmorpholine (NMM), dichloromethane, piperidine, trifluoroacetic acid (TFA), anisole, thioanisole, and triisopropylsilane) were purchased from Sigma.

Synthesis of the different A β Peptides were performed on a Gyros-Protein Technologies, Inc., prelude synthesizer at a 25 μ mol scale using a 10-fold excess of Fmoc-amino acid relative to the preloaded Fmoc-Gly-wang-LLresin (0.33 mmol/g) or Fmoc-Ala-wang-LLresin (0.33 mmol/g). Fmoc-protected amino acids were used with the following sidechain protections: tert-butyl ester (Glu and Asp), tert-butyl ether (Ser and Tyr), trityl (His, Asn, and Gln), tert-butoxycarbonyl (Lys). Amino acids were coupled twice for 5 min using 1:1:2 amino acid/HCTU/NMM in NMP. After incorporation of each residue, the resin was acetylated for 5 min using a 50-fold excess of a mixture of acetic anhydride and NMM in NMP. Fmoc deprotection was performed twice for 3 min using 20% piperidine in NMP, and 30 sec NMP top washes were performed between deprotection and coupling and after acetylation steps. Biotinylation of APP peptide was performed on the resin after Fmoc deprotection of the N-terminal residue, using a 10-fold excess of N-biotine-NH(PEG)X-COOH and HCTU and NMM as coupling reagents (see above).

After completion, the peptidyl-resins were treated with a mixture of TFA/thioanisole/anisole/TPS/water (82:5:5:2.5:5) for 2 h. The crude peptides were obtained after precipitation and washes in cold ethyl ether followed by dissolution in 10% acetic acid and lyophilization.

Peptides were purified by reverse phase HPLC using an X-Bridge BHE C18-300-5 semi-preparative column (Waters, USA) (250 x 10 mm; 4 ml·min⁻¹; solvent A, H₂O/TFA 0.1%; solvent B, acetonitrile/TFA 0.1% using a gradient of 0-60% solvent B into A in 60 min. The purity of each peptide

was checked by mass spectrometry using ESI-MS (Bruker). Lyophilized peptides were solubilized in water-acetonitrile (50%) and stored at -80 °C.

Site-directed mutagenesis

APP-mCherry was mutated at single or double sites using the QuickChange II Site directed mutagenesis kit (Agilent) following provider-issued recommendations. Parental methylated DNA was degraded following digestion with *DpnI* and the remaining mutated DNA was transfected in competent XL1-Blue *E. Coli* (Invitrogen). Transformed Bacteria were selected on Petri dishes filled with medium containing kanamycin (30 mg/mL) (Invitrogen). In total 7 single and 2 double point mutations were produced in the cholesterol-binding site, in the juxtamembrane region of APP, at positions 22, 26, 28, 29, 33 and 39 of the A β sequence. Mutants are illustrated in Fig. 1B.

Cell culture, transfection and treatments

HEK293 cells were grown in DMEM-glutamax medium (Gibco, Thermofisher Scientific) supplemented with 10% fetal calf serum (Invitrogen, CA, USA) and 1% penicillin/streptomycin (Gibco) at 37 °C and 5% CO₂. Transfection experiments were carried out on HEK 293T cells with 70% confluence in OptiMEM medium (Gibco) without antibiotic using lipofectamine 2000 (Invitrogen). 0.7 μ g of plasmid was diluted in 100 μ L of OptiMEM medium (Gibco). In parallel, 4 μ L of lipofectamine 2000 (Invitrogen) were mixed with 100 μ L of OptiMEM medium. Transfection was performed according to manufacturer's instructions (Invitrogen). After deposition of the transfection mix, the cells were placed for 4 hours in the incubator at 37 °C, washed with 1X PBS to remove any trace of transfectant and then incubated with complete medium: DMEM medium supplemented with 10% fetal calf serum and 1% penicillin-streptomycin (Gibco).

Treatment with DAPT: In order to analyze the cleavage of APP-mCherry mutants by the β - and γ -secretases, 24 hours after transfection, cells were treated for 16 hours with N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-phenylglycine T-butyl ester (DAPT) (Sigma Aldrich), an inhibitor of γ -secretase, diluted to a concentration of 5 μ M in complete new medium.

Cholesterol treatment: 24 hours after transfection HEK cells were washed twice with DMEM medium (Gibco), treated for 30 min with 1.4 mM M β CD-cholesterol (Sigma), dissolved in DMEM medium and then washed three times with DMEM medium.

Protein extraction and western blot

The HEK293T cells were washed with 1X PBS and then lysed on ice using a buffer RIPA (50 mM Tris-HCl pH 8.0, 150 mM sodium chloride, 1.0% NP-40, 0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate) (Sigma Aldrich), to which were added Phenylmethylsulfonyl fluoride 100X (Sigma Aldrich) and a cocktail of inhibitors of proteases (Complete Mini, Roche). The lysates were sonicated 3 times for 5 min then stored at -80 °C. Protein concentration of the lysates was quantified by

Bradford assay (Biorad) according to the manufacturer's instructions. Western blots were made from the cell lysates of HEK293T cells treated with DAPT. Proteins from cultured lysates HEK293T were separated in 16.5% Tris-Tricine (Biorad) polyacrylamide gels. Proteins were transferred to a polyvinylidene difluoride membrane (Biorad) at 150 V for three hours at 4 °C. After 1 hour of saturation with 10 % milk, membranes were incubated overnight at 4 °C with primary antibodies directed against APP and actin β proteins diluted to 1/2000 in BSA-azide 2 % solution. Membranes were incubated with fluorescent secondary antibodies (diluted to 1/10,000 in 0.05 % TBS-tween solution) for 1 hour under agitation at room temperature and away from direct light. The revelation and quantification of fluorescence were carried out by Odyssey's analysis software (Set up ImageStudio CLx) (Odyssey Clx LI-COR).

Confocal imaging

HEK293 cells cultured on poly-D-lysine-coated coverslips were fixed 24 hours after transfection using a solution of 4% paraformaldehyde in PBS for 15 min at room temperature. Cells were first incubated with anti-EEA1 antibody (1/500, Cell Signaling) and then with goat anti-rabbit secondary antibody conjugated to Alexa 488 (1/1000, Cell Signaling). Coverslips were mounted in Fluoromount medium (Southern Biotech, AL, USA). Z-stack of cells were acquired on a Fluoview FV1000 confocal microscope (Olympus, Tokyo, Japan). Fluorescence was collected with a 60x plan apochromat immersion oil objective (NA 1.35). The mean endosomes size and number per cell were analyzed with ICY software. Between 7 and 10 cells were analyzed.

A β 38, 40 and 42 measurements

Supernatants of HEK cells were collected on ice 24 hours after transfection in polypropylene tubes, containing phosphatase inhibitor cocktail (Complete Mini, Roche). Supernatants were then stored at -80 °C. Concentrations of the A β 38, A β 40 and A β 42 species of β -amyloid peptide were measured by multiplex Electro-Chemiluminescence Immuno-Assay (ECLIA). Assays were performed according to the manufacturer's instructions (Meso Scale Discovery (MSD) Meso QuickPlex SQ120). 100 μ L of blocking buffer solution were first added to all wells to avoid non-specific binding. The plates were then sealed and incubated at room temperature on a plate shaker (450 rpm) for 1 hour. Wells were then washed three times with washing buffer, and 25 μ L of the standards peptides (A β 38, A β 40, A β 42) (MSD) and samples were then added to the wells, followed by an A β -detecting antibody at 1 μ g/ml labelled with a Ruthenium (II) trisbipyridine N-hydroxysuccinimide ester (MSD). This detection antibody was 6E10 (raised against the common epitope A β 1-16 of the human peptide, therefore the 3 A β 38, A β 40, A β 42) (MSD). Plates were then aspirated and washed 3 times. MSD read buffer (containing tripropylamine as co-reactant for light generation in the electrochemiluminescence immunoassay) was added to wells before reading on the Sector Imager. A small electric current passed through a microelectrode present in each well to produce a redox reaction of the Ru²⁺ cation, emitting 620 nm red

lights. The concentration of each A β peptide was calculated in pg/ml for each sample, using dose–response curves. It was then normalized by protein concentration measured by Bradford assay (Bradford).

A β (1-x) measurements

Supernatants of HEK cells were collected on ice 24 hours after transfection in polypropylene tubes, containing phosphatase inhibitor cocktail (Complete Mini, Roche). Supernatants were then stored at -80 °C. Concentrations of peptides A β 28, 40 and 42 were measured by immune-enzymatic assay (ELISA) using the IBL A β (1-x) kit. This kit is a solid phase ELISA sandwich using 2 kinds of highly specific antibodies. Assays were performed according to the manufacturer's instructions. Samples were plated in 96-well plates, containing antibodies specific for the A β (Precoated plate: Anti-Human A β (N)(82E1) Mouse IgG). Briefly, 100 μ l of sample or 100 μ L of A β 40 synthetic peptides (used as the standard range, IBL) were deposited in 96-well plates. The plates were sealed and incubated overnight at 4 °C with gentle agitation. After several washings of the plates (minimum 7), 100 μ l of anti-A β antibody solution (Mouse IgG directed against the epitope 11-28 of the human A β peptide, IBL) coupled to horseradish peroxidase (HRP) were deposited in the wells. The plaques were then sealed and incubated for one hour at 4 °C with gentle agitation. The plates were then washed 9 times with a wash buffer. 100 μ L of a solution containing a Tetra Methyl Benzidine colorimetric agent, were deposited in the wells. After 30 minutes of incubation at room temperature and protected from light, a stop solution was deposited. Absorbance was measured at 450 nm (Thermo multiskan EX, Thermo Fisher Scientific) within 30 minutes of depositing the stop solution. The concentration of each A β peptide was calculated in pg/ml for each sample, using dose–response curves. It was then normalized by the protein concentration measured by Bradford assay (Bradford).

Immunoprecipitation

Four μ g of the A β -specific antibodies 6E10 (1-16, Biolegend) and 4G8 (17-24, Biolegend) were added separately to 25 μ L of Dynabeads M-280 sheep anti-mouse (ThermoFisher Scientific) suspension, according to the manufacturer's description. The washed antibody-bead complexes were combined (50 μ L in total) and added to 3 ml supernatants of HEK cells together with 20% (v/v) Triton X-100 to a final concentration of 0.2% (m/v) and incubated overnight at +4 °C. The beads/sample complex was transferred to the KingFisher for automatic washing (in 0.2% Triton X-100, phosphate-buffered saline (PBS), pH 7.6, and 50 mM ammonium bicarbonate) and elution in 0.5% FA (v/v). The eluate was dried down in a vacuum centrifuge pending MS analysis.

Mass spectrometry

Analysis by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) was performed using an UltraFleXtreme instrument (Bruker Daltonics) in reflector

mode. Prior to analysis samples were reconstituted in 5 μ l 0.1% FA/20% acetonitrile in water (v/v/v). MALDI samples were prepared using the seed layer method as previously described (28). An average of 10,000 shots was acquired for each spectrum (2000 at a time using a random walk mode). The unused sample (3 μ l) was further dried down in a vacuum centrifuge and further analysed by nanoflow liquid chromatography (LC) coupled to electrospray ionization (ESI) hybrid quadrupole–orbitrap tandem MS (MS/MS), see below.

Analysis by nanoflow LC-ESI-MS/MS (Dionex Ultimate 3000 system and Q Exactive, both Thermo Fisher Scientific) was performed in a similar way as described previously (29, 30). Briefly, samples were reconstituted in 7 μ l 8% FA/8% acetonitrile in water (v/v/v). An Acclaim PepMap 100 C18 trap column (20 mm $\times$ 75 μ m, particle size 3 μ m, pore size 100 Å, Thermo Fisher Scientific) was used for online desalting and cleanup. For separation a reversed-phase Acclaim PepMap RSLC column (150 mm $\times$ 75 μ m, particle size 2 μ m, pore size 100 Å, Thermo Fisher Scientific) was used. Mobile phases were 0.1% FA in water (v/v) (A) and 0.1% FA/84% acetonitrile in water (v/v/v) (B). Separation was performed at a flow rate of 300 nl/min by applying a linear gradient of 3%–40% B for 50 min at 60 °C. Spectra were acquired in positive ion mode for the mass-to-charge (m/z) range 350–1800. Both MS and MS/MS acquisitions were obtained at a resolution setting of 70,000 using 1 microscan, target values of 10^6 , and maximum injection time of 250 ms. MS/MS acquisitions were obtained using so-called higher-energy collisional dissociation fragmentation at a normalized collision energy setting of 25, an isolation window of 3 m/z units, and exclusion of singly charged ions and ions with unassigned charge.

Database search, including isotope and charge deconvolution, and peak area determination, was performed with PEAKS Studio X+ (Bioinformatics Solutions Inc.) against a custom-made APP database, which included the K28A modified sequence. All suggested fragment mass spectra were validated manually. For the label-free quantitative analysis, normalization was performed for each sample by division of the raw area with the total protein content (as determined by the Bradford assay, see above).

Purification of exosomes from HEK293T cell culture medium

HEK293T cells were grown in DMEM 10% FCS in T150 flasks coated with Poly-lysine. At 80 % confluence, cells were rinsed in PBS 1X heated at 37 °C and resuspended in OPTIMEM without FCS and incubated at 37 °C during 24 hours. Culture medium was collected in 50 mL Falcon tubes then centrifuged at 2000 g for 20 min at 4 °C. Supernatant was filtered through 0.22 μ m Millipore filters and centrifuged at 100,000 g for 2 hours at 4 °C. Pellets containing the exosomes were rinsed with ice-cold PBS, centrifuged again at 100,000 g for 2 hours at 4 °C and resuspended in 75 μ L ice-cold PBS. The size of exosomes was measured using Dynamic Light Scattering (mean radius 400 nm, polydispersity 25 %). Cholesterol was assessed separately using the AmplexTM Red Cholesterol Assay Kit from Invitrogen (Thermo Fisher Scientific).

Binding of amyloid peptides to exosomes

Peptides (15 μ L at 20 μ M) were incubated with 10 μ L of exosomes (cholesterol at 30 μ M) in 50 μ L final volume complemented with PBS at 37 °C for 1 hour under agitation, in 2 mL Eppendorf tubes (allowing maximum agitation). Solutions were diluted in 400 μ L PBS and deposited on a sucrose gradient in 5 mL tubes (from bottom to top: 3.6 mL 60 % sucrose solution in PBS, 600 μ L 50 % sucrose solution and 400 μ L 10% sucrose solution - the exosome + peptide mix is at the top), and centrifuged at 140,000 g for 2 hours in a swinging rotor. 11 Fractions were collected: 1 to 4 of 200 μ L, 5 to 7 of 300 μ L and the next 4 fractions of 1 mL. Concentrations of peptides were measured by immune-enzymatic assay (ELISA) using biotin-streptavidin-HRP detection. Assays were performed according to the manufacturer's instructions. Briefly, 25 μ L of each fraction were deposited in 96-well plates (Immunoplate, Nunc). The plates were sealed and incubated overnight at 4 °C with gentle agitation. After 3 washings of the plates in PBS, 100 μ L BSA 1% in PBS was added for one hour followed by 3 washings in PBS. Streptavidin solution coupled to horseradish peroxidase (HRP) (Sigma) in PBS (1/2500 dilution) were deposited in the wells (100 μ L). The plaques were then sealed and incubated for one hour at 4 °C with gentle agitation. The plates were then washed 3 times with 0.05 % PBS-tween solution. After 30 minutes of incubation at room temperature with 3,3', 5, 5'- tetramethylbenzidine (TMB Peroxidase EIA Substrate Kit, Biorad), a stop solution (H₂SO₄ 2M) was deposited. Absorbance was measured at 450 nm (Varioscan) within 30 minutes of the deposition of the stop solution.

Statistical analysis

All analyses were performed using GraphPad Prism version 6.00 for Windows. Statistical tests were two-tailed and conducted at a 5% significance level. Student t test was performed to compare mutant vs control condition and non-parametric Mann and Whitney t test was applied for small datasets ($n \leq 4$).

Data were derived from 3 independent cultures with 2 to 3 replicates per culture, except confocal imaging which was performed on 1 culture and 7 to 10 cells per condition. Data are presented as mean $\pm$ SEM.

Results

Production of APP mutants of the cholesterol-binding site (CBS):

Starting from the structural study that characterized the CBS on APP (22) (Fig. 1A), we used site-directed mutagenesis to produce point mutations in the APP⁷⁵¹mCherry plasmid. In total seven mutants were generated in the juxtamembrane region at positions 22, 26 and 28, and in the transmembrane region at positions 29, 33 and 39 of the A β sequence (positions 673, 677 and 679, and positions 680, 684 and 690 of APP⁷⁵¹). In addition, we produced two double mutants at juxtamembrane positions 26/28 and at transmembrane positions 29/33 (Fig. 1B). Point mutations corresponded to either inversion of charge of the mutated amino acid such as in the E22K and the K28E mutants, suppression of charge as in the K28A mutant, decrease of hydrophobicity as in the V39A mutant or increase of hydrophobicity as in the S26A, G29A and G33A mutants (Fig. 1B). These changes of either charge and/or hydrophobicity at these positions have been shown by NMR to alter the cholesterol-binding properties (22). All plasmids were sequenced and the mutations confirmed.

Dosage of A β peptides produced by HEK293T cells transfected with APP mutants of the CBS:

We used the Meso Scale Discovery multiplex ELISA for dosage of A β 38, A β 40 and A β 42 using capture antibodies recognizing the C-terminal part of the A β sequence (neoepitope ending at amino acid 38, 40, 42, respectively) and a detection antibody binding to the N-terminal part of A β (4-9) by Electro-Chemiluminescence. All mutations produced were localized outside the epitopes of both the capture and the detection antibodies. As described previously, we found that the levels of A β 40 secreted by HEK293 cells were higher than the levels of secreted A β 42 (data not shown) as suggested earlier (18, 31). We found that mutations at positions 28 and 39 dramatically reduced the secretion of A β 40 and A β 42 as compared with APP^{WT}, while the effect was weaker with mutations at positions 22, 26, 29 and 33 (Fig. 2A,B). Secretion of A β 38 was undetectable with all transfected plasmids. We then asked whether the large decrease in A β 40/42 secretion by HEK293T cells transfected with mutated APP⁷⁵¹ was due to an accumulation of intracellular peptides or to differences in APP processing. Since the MSD Multiplex assay can only quantify full length A β 38, A β 40 and A β 42, we used the IBL ELISA with a capture antibody that targets the N terminus of A β peptides and a detection antibody raised against A β 11-28 of A β , able to measure shorter A β peptides (A β 1-x with x $\geq$ 16) in addition to A β 38, A β 40 and A β 42. Using this IBL kit, we found that mutants at positions 26 and 28 and the double mutant 26/28 secreted significantly more A β 1-x peptides with x $\geq$ 16 while all other mutants showed decreased secretion (Fig. 2C). As the secretion of A β 40 and A β 42 was reduced using these mutants (Fig 2A, B), we concluded that mutants at positions 26 and 28 and the double mutant 26/28 secreted shorter peptides within the range A β x-16 to A β x-42.

Altogether, we showed that mutating the CBS of APP at positions 26 and 28 of the A β sequence altered the size of A β peptides produced while mutations at positions 22, 29, 33 and 39 decreased the amount of secreted A β peptides ranging from A β 16 to A β 42. Mutation at position 28 gave the strongest

effect compared to mutation at position 26, while the double mutant (positions 26 and 28) showed cumulative effect, particularly for shorter A β peptides (Fig. 2C).

We then asked whether the large decrease in A β 40 and A β 42 secretion was due to an accumulation of intracellular peptides or to differences in APP. We used the MSD assay to measure intracellular A β 38, 40 and 42. In Fig. 2D, we found again less although non-significant accumulation of the intracellular A β 40 in HEK293T cells transfected with the mutants at positions 28 and the double mutant 26/28 than with the APP^{WT}. Levels of A β 42 and A β 38 were undetectable.

Processing of APP^{WT} and APP^{K28A}:

We then characterized the APP mutant K28A (APP^{K28A}) which showed the most contrasted profile of A β secretion. Because of the large decrease of A β 40 and A β 42 secretion observed in HEK293T cells transfected with APP^{K28A}, we tested the activity of the α -, β -, and γ -secretases by quantifying the levels of full length APP, C-terminal fragments (β CTF) and AICD (APP intracellular domain) in the presence or absence of the γ -secretase inhibitor, the dipeptide DAPT. In the absence of DAPT the activities of α - and β -secretases are measured through the production of AICD (Fig. 3C). In the presence of DAPT, production of AICD is inhibited, thus allowing quantification of β CTFs reflecting the activity of β -secretase only (Fig. 3B). Using western blot quantification, Fig. 3 shows that the levels of full length APP^{mCherry} did not vary between transfections (data not shown). Moreover, β CTFs were significantly but modestly decreased in cells transfected with APP^{K28A} compared to cells transfected with APP^{WT} while the levels of AICD remained unchanged. Of note, the small decrease of β CTFs observed with APP^{K28A} in Fig. 3 did not compare with the dramatic drop in secretion of A β 40 and 42 (Fig. 2A-B) or in intracellular expression of A β 40 (Fig. 2D) within cells transfected with APP^{K28A} compared to cells transfected with APP^{WT}. Overall, α -, β -, and γ -secretases activities were not modified by CBS mutation.

Subcellular localization of APP^{WT} and APP^{K28A}:

Since APP processing occurs in the endolysosomal compartment, we compared the percentage of colocalization of APP^{WT}-mCherry and APP^{K28A}-mCherry with an anti-EarlyEndosomeAntigen1 (EEA1) antibody in transfected HEK293T cells. Fig. 4 clearly shows that APP^{WT} and APP^{K28A} similarly localized in the early endosomal compartment, strongly suggesting that subcellular localization of APP^{WT} and APP^{K28A} in early endosomes was comparable.

Effect of cholesterol treatment of stable HEK293T clones expressing APP^{WT} and APP^{K28A} on A β 40 and A β 42 production:

We wanted to test whether the addition of cholesterol in the plasma membrane, known to trigger APP processing and A β production, was able to do so in cells expressing the APP^{K28A} mutant. We first produced HEK293T clones stably expressing APP^{WT} and APP^{K28A} and selected those which expressed

similar levels of the protein APP-mCherry (clones 1H4 and 2E5 in Supplementary Fig. 1). We confirmed that clone 2E5 expressing APP^{K28A} produced significantly less A β 40 and A β 42 peptides as compared to clone 1H4 that expressed APP^{WT} (Fig. 5 and Supplementary Fig. 1). HEK293T clones stably expressing APP^{WT} and APP^{K28A} were treated with methyl- β -cyclodextrin (MBCD) loaded with cholesterol as described previously thus inducing a 15-20 % increase of membrane cholesterol concentration (14, 16). While cholesterol increase at the plasma membrane raised A β 40 and A β 42 secretion in APP^{WT} expressing clone, APP^{K28A} clone expressing the CBS mutant, as expected, was insensitive to cholesterol changes (Fig. 5).

Effect of cholesterol treatment of stable HEK293T clones expressing APP^{WT} and APP^{K28A} on A β peptides profile using mass spectrometry:

In order to confirm that K28A mutation in APP changes the A β profile of peptides secreted from longer towards shorter size, we analyzed the supernatants of HEK293T clones stably expressing APP^{WT} and APP^{K28A} using MALDI-TOF-MS and LC-ESI-MS and -MS/MS. A different A β peptide pattern was observed between APP^{WT} and APP^{K28A} samples (Figure 6). In APP^{WT} samples the full length A β 1-40 is present, together with several N-truncations of A β x-37/38/39/40, while these peptides are absent in the APP^{K28A} samples, where A β x-33/34 are the major forms identified. A full list of the peptides identified by LC-ESI-MS/MS is shown in Supplementary Table. Cholesterol treatment of HEK293 cells transfected with APP^{WT} or APP^{K28A} did not modify the profile of secreted A β peptides.

Binding of A β -derived peptides to membranes of exosomes purified from HEK293T cells:

Next we wanted to test whether mutations of the CBS in the juxtamembrane segment of APP could change the interaction with lipid bilayers formed by natural membranes. Three peptides corresponding to the juxtamembrane region of APP (positions 15 to 33 on A β) were synthesized with a linker and a biotin (Fig. 7). In addition to A β 15-33^{WT} and A β 15-33^{K28A}, we synthesized A β 15-33^{E22K} peptide carrying the Italian mutation found in familial cases of AD. Cholesterol-rich exosomes secreted by untransfected HEK293T cells were purified by ultracentrifugation and incubated with the three peptides for 1 hour at 37 °C. Peptides bound to exosomes were separated on a sucrose gradient and quantified by luminescence with streptavidin coupled to HRP. Fig. 6 shows that A β 15-33^{WT} bound specifically to exosomes while A β 15-33^{E22K} and A β 15-33^{K28A} did not, thus confirming that K28A mutation in the CBS alters the binding of A β 15-33 peptides to cholesterol containing natural membranes.

Discussion

Our previous work demonstrated that membrane cholesterol is an important factor modulating the processing of the transmembrane protein APP and hence the production of toxic A β peptides. We found that transient increase of cholesterol at the plasma membrane of non-neuronal and neuronal cells induces a rapid relocalization in lipid rafts of APP and the β -secretase BACE1, the first APP-processing enzyme of the amyloid pathway (14, 15). This was followed by a rapid internalization of APP-BACE1 complex in endosomes with larger size and an increase of A β 40/42 secretion (14-16).

We show here that mutations in the transmembrane or in the juxtamembrane regions of APP involved in cholesterol-binding differentially regulate APP processing. Point mutations in the APP transmembrane domain modulating the hydrophobicity of specific residues at position 29 (G29A), 33 (G33A) involved in the GxxxG dimerization motifs, and 39 (V39A) of the A β sequence lead to a significant reduction of the secretion of A β peptides (A β 40 and A β 42 as well as shorter A β 1-x with $x \geq 16$ peptides, which we show was not due to any accumulation of intracellular A β peptides. In addition, the double mutation G29A and G33A provided more dramatic and cumulative effects on A β secretion. Reduction of A β secretion by mutations in the glycines of the GxxxG could thus be due not only to differences in cholesterol binding but also result from inhibition of the γ -secretase as was found previously (32). Interestingly, here we show that point mutations in the APP juxtamembrane domain producing either an increase of hydrophobicity (S26A) or a change of charge (E22K, S26A, K28A and K28E) had different effects on A β secretion. While the E22K mutant produced significantly less A β 42 and A β 28-42, all three others mutants (S26A, K28A and K28E) showed lower levels of A β 42 but higher levels of A β 1-x with $x \geq 16$ peptides, with K28A giving the most contrasted differences. Interestingly the secreted A β peptide profile from the double mutant S26A and K28A was more similar to K28A profile as compared to S26A thus indicating that the K28A mutation prevailed.

Two important residues from the juxtamembrane segment namely E22 and D23 have been found to control pH-dependant binding of cholesterol to APP (33). At low pH, such as in the endosomal compartment, E22 and D23 are neutral and bind cholesterol thus allowing APP processing by the β - and γ -secretases while change of charge as in the E22K mutant alters this processing. This glutamic acid at position 22 of A β is mutated in several dominant familial cases of AD (FAD) surprisingly showing low levels of A β peptides. As mirrored here in cellular models, the Italian mutation E22K produces low levels of A β 42 in the brain of affected individuals with prominent cerebral amyloid angiopathy and lack of neurofibrillary tau and neuritic plaques (34, 35). Here we found that binding of the corresponding synthetic mutated peptides derived from the juxtamembrane region of A β (A β 15-33^{E22K}) to lipid bilayers formed by cholesterol rich natural membranes was largely decreased as compared to A β 15-33^{WT} peptide. This change of interaction could induce the juxtamembrane loop to exit the plasma membrane. Indeed, it was shown previously that the A β 22-35 region is linked to cholesterol in the lipid bilayer (36). In Fig. 1 we represent equal levels of membrane cholesterol in the two leaflets. However, the exact ratio of cholesterol between outer and inner leaflets has not been definitively clarified (37) but several authors

suggest that there could be ten times more cholesterol in the outer leaflet than in the inner leaflet (38, 39). This later property could favour the binding of the APP juxtamembrane region to the enriched cholesterol leaflet.

Other pathological mutations at position E22 have been identified and show changes in A β formation. Arctic mutation carriers (E22G) have lower levels of A β 40/42 while A β protofibrils are increased (40). In addition, individuals carrying the E22Q Dutch mutation show hereditary cerebral haemorrhage with Dutch-type amyloidosis with characteristic cerebral amyloid angiopathy and an increased formation of oligomeric and fibrillar A β (35). Change of binding of cholesterol following mutations at position E22 remains to be demonstrated *in vivo*.

The profile of A β secreted by S26A, K28A and K28E mutants of APP were similar to each other with a decrease of A β 42 and an increase of A β 28-42 suggesting that shorter A β peptides are produced by these mutants. In addition, other mutants at positions S26 and K28 namely S26L and K28S were also found to produce large decrease of A β secretion (41). Using MS methods we confirmed that the K28A mutant produced mostly A β 33 and A β 34 peptides with no detectable levels of A β 40 or A β 42, in line with a previous study (42). These authors suggested that the change in the length of secreted A β peptides induced by the K28A mutation was due to a shift in the primary cleavage site of the γ -secretase without significant change to the ϵ cleavage occurring between L49 and V50 and producing AICD. In this model, the lysine at position 28 anchors the A β sequence at the juxtamembrane thus limiting the accessibility to the stationary transmembrane γ secretase. Mutating this lysine would suppress the anchoring thus allowing entry in the transmembrane γ secretase active site (42).

Here we propose that interaction of lysine at position 28 with membrane cholesterol participates in the anchoring of the A β 22-28 sequence at the juxtamembrane. Mutating this lysine at position 28 suppressing cholesterol-binding will “de-staple” the A β region of APP, thus allowing the entry of the sequence in the membrane and permitting cleavage by γ -secretase at positions 33-34. Previous molecular dynamics simulations have shown that K28A mutation reduces intrapeptide hydrophobic interactions between E22/D23 and K28 (43) and increases helix content while decreasing β -sheet and hydrophobic contacts and electrostatic interactions (44, 45). The K28A mutation would thus not only reduce the interaction with cholesterol but also decrease intrapeptide interactions. Evidence for this may be summarized as follows.

First, we show that APP^{K28A} produces shorter size A β peptides (A β x-33/34) without any change in the levels of AICD. Second, we found that the APP^{K28A} mutant is insensitive to the effect of membrane cholesterol increase on A β secretion with no change in the levels nor the profile of A β peptides. According to our previous work (14-16) and the data presented here, transient membrane cholesterol increase triggers APP^{WT} processing and A β 40/42 secretion. Remarkably, this effect of cholesterol was not observed with the APP^{K28A} mutant. This change was unlikely due to difference of endocytosis since the subcellular localization of APP^{K28A} and APP^{WT} in the endosomal compartment were similar. Third, binding of the corresponding synthetic mutated engineered peptides derived from the juxtamembrane

region of A β (A β 15-33^{K28A}) to lipid bilayers formed by natural membranes was largely decreased as compared to A β 15-33^{WT} peptide. Thus the affinity of A β 15-33^{K28A} and A β 15-33^{E22K} for the cholesterol rich membrane is reduced, therefore their tilting within the membrane and in particular within the outer leaflet should be modified. Consequently, these CBS mutants appear to different positions in the plasma and intracellular membranes and induced changes in their cleavage by γ -secretase produces shorter A β peptides.

A β 34 is produced through degradation of A β 40 and 42 but not β CTF by BACE1 (46, 47). It is present in the brain of AD patients and 3xTg mice (48) and is elevated in individuals with mild cognitive impairments at risk for dementia, correlating with amyloid positivity and pericyte mediated clearance (49-51). Here we show that APP cleavage by BACE1 is not affected by the K28A mutation. However, whether degradation of A β 40^{K28A} and A β 42^{K28A} by BACE1 is favoured remains to be shown using synthetic peptides and reconstituted BACE1 protein. However it is quite unlikely since we show that K28A mutation mostly produces A β 33 peptides that are not degraded from A β 34 by the matrix metalloproteases MMP-2 and MMP-9 (52).

Conclusions

Collectively, the present data demonstrate that specific mutations in the juxtamembrane segment of the cholesterol-binding site of APP lead to the production of shorter A β peptides, likely by altering the anchoring and positioning of APP in the plasma membrane. By allowing access to the active transmembrane γ secretase site, this results in an increase in APP processing. A tight regulation of membrane cholesterol is particularly important at the presynaptic terminals of neuronal cells where APP is enriched and its expression, distribution and processing are regulated by synaptic activity (53, 54). Thus, together with neuronal activity, the cholesterol content of membranes and the CBS on APP could play a critical role in regulating APP processing and the resulting amount, size and toxicity of A β peptides.

These observations underpin interest in central cholesterol as a potential target for the treatment of AD and several strategies have proven successful in preclinical models (55). For example, CYP46A1 overexpression to accelerate brain cholesterol clearance reduces amyloid pathology and improves cognitive deficits in murine models for AD (56). Intriguingly, and suggesting the broader relevance of cholesterol, in cultured neurons cholesterol has been shown not only to regulate A β secretion through its interaction with the APP CBS, but also tau pathology *via* a different mechanism involving the proteasome (57). The present results establish a role of the juxtamembrane region of APP containing the CBS as a regulator of the size of A β peptides produced by processing of APP processing: this specific region could then be a novel target for inhibiting cholesterol-binding and reducing the production of toxic A β species. K28 has been targeted using lysine-specific molecular tweezers to inhibit assembly and toxicity of amyloid peptides (58-60). It will be of interest to determine whether editing of this residue

using CRISPR Cas9, antisense knockdown of the mutant protein, or treatment with antibodies targeting the juxta-membrane region will alter APP processing.

List of abbreviations

A β - amyloid- β

AD - Alzheimer's disease

AICD - APP intracellular domain

APOE - apolipoprotein E

APP - Amyloid Precursor Protein

CBS - cholesterol-binding site

β CTF - C-terminal fragment

DAPT - *tert*-Butyl (2*S*)-2-[[[(2*S*)-2-[[2-(3,5-difluorophenyl)acetyl]amino]propanoyl]amino]-2-phenylacetate

EEA1 - EarlyEndosomeAntigen1

MBCD - methyl- β -cyclodextrin

TMD - transmembrane domain

Declaration

The datasets generated and/or analysed during the current study are available from the corresponding author on request.

Competing interests

HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). MJM is a full-time employee of Servier Pharmaceuticals and has no other interest to declare.

Funding

This work was supported by 'Investissements d'avenir' ANR-10-IAIHU-06, Institut de Recherche Servier. LH was supported by a fellowship from Institut de Recherche Servier. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), and the UK Dementia Research Institute at UCL.

Authors' contribution

LB, MCP, CM, BS, NG and LH made substantial contributions to the conception and design of the work; LH, BS, AK, GF, EG, GB, participated in the acquisition, analysis, and interpretation of data; MCP, LB, BS, EP, KB, HZ, MJM have drafted the work or substantively revised it and all authors have approved the submitted version and have agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.

Conflicts of interest

HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). MJM is a full-time employee of Servier Pharmaceuticals and has no other interest to declare.

Acknowledgements

The authors wish to thank Inger Lauritzen and Frédéric Checler from IBPC Sophia Antipolis for protocols for exosome purification and important discussions on A β 34 respectively, Karen Perronet and Julien Moreau from Institut d'Optique Paris-Saclay for useful discussions and Bernadette Allinquant and Serge Marty for critical reading of the manuscript. This work was supported by 'Investissements d'avenir' ANR-10-IAIHU-06, Institut de Recherche Servier. LH was supported by a fellowship from Institut de Recherche Servier. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), and the UK Dementia Research Institute at UCL.

Figure legends

Figure 1: Schematic diagram of the juxta- and the trans-membrane regions of APP CTF β within the membrane, inspired from (22). Cholesterol is highlighted in red. **(A):** Amino acid sequence of the APP^{WT} and mutations from Familial Alzheimer Disease (FAD) cases. **(B):** Indication of the mutations produced in the cholesterol-binding site (CBS) shown at positions 22, 26, 28, 29, 33 and 39. Numbering according to A β . Various colors indicate the type of changes in the mutants.

Figure 2: Mutations in the CBS modulate the A β secretion in transfected HEK293T cells without accumulation in the intracellular compartments. **(A, B, D):** MSD assay of extracellular A β 40 and A β 42 levels respectively, on transfected HEK293T with different mutants of the APP CBS. The results are normalized with the amount of intracellular proteins determined by Bradford assay and represented as a percentage of A β produced by APP^{WT}. **(C):** ELISA (IBL kit) for A β (1-x with $x \geq 16$) extracellular levels on HEK293T transfected with the different APP mutants. The results are normalized with the amount of intracellular protein determined by Bradford assay and normalized to percentage of A β produced by transfected HEK293T cells with APP^{WT}. Numbering according to A β (t test, mean $\pm$ SEM, *: $p < 0.05$, **: $p < 0.01$, ***: $p < 0.001$, comparison with APP^{WT}, 3 independent cultures with 2 to 3 replicates per culture $6 < n < 9$).

Figure 3: Effect of K28A mutation in the CBS on the activity of α , β and γ -secretase in transfected HEK293T. **(A):** Western blot of HEK cell lysates transfected with APP^{WT} and APP^{K28A}. The relative levels of CTFs **(B)** and AICD **(C)** fragments generated by the juxtamembrane mutation K28A are normalized by transfection rates (level of APP-mCherry). (Test Mann Whitney, mean $\pm$ SEM, *: $p = 0.0260$, 3 independent cultures with $4 < n < 6$).

Figure 4: Effect of K28A mutation on endosomal localization of APP-mCherry. Effect of K28A mutation on endosomal localization of APP-mCherry. HEK293T cells were transfected with APP^{WT}-mCherry or APP^{K28A}-mCherry, fixed after 24 hours and immunolabelled for early endosomes using an anti-EEA1 antibody. **(A)** Arrows indicate APP^{WT}-mCherry or APP^{K28A}-mCherry in EEA1-positive early endosome. **(B)** Percentage of colocalization of the two fluorescent signals mCherry and Alexa488 was quantified from single stack of images acquired on the confocal microscope. The values are given as mean $\pm$ SEM **(B)**. Statistical differences were analyzed by t test, $7 < n < 10$ cells/experiment.

Figure 5: The K28A mutation in the CBS of APP abolishes the modulation of A β secretion by cholesterol increase at the plasma membrane. MSD assays for secreted A β 40 **(A)** and A β 42 **(B)** levels from HEK293T clones stably expressing APP^{WT} and APP^{K28A} in the absence and in the presence of additional methyl- β -cyclodextrin (MBCD) loaded with cholesterol. The results are normalized with the amount of intracellular proteins determined by Bradford assay and represented as a percentage of A β

produced by APP^{WT} in the absence of MBCD loaded with cholesterol. . (Test two-way ANOVA, 4 independent experiments/culture with 2 <n <6).

Figure 6: MALDI mass spectra of APP^{WT} and APP^{K28A} both treated with cholesterol (+cholesterol) and untreated (-cholesterol). An A β pattern difference between APP^{WT} and APP^{K28A} is observed, with A β X-37/38/39/40 present in WT while A β X-33/34 peptides are the most abundant in APP^{K28A}.

Figure 7: Effect of mutations of the CBS in the juxtamembrane segment of APP on their binding to exosomes. Evaluation of the amount of biotinylated peptides floating in an 11 mL sucrose gradient after incubation with and without exosomes and ultracentrifugation. Biotinylated peptides were quantified by ELISA assay using HRP-streptavidin (n=3). Ratio of bound peptides corresponds to biotine signal in the first 4 fractions (0 and 10% sucrose) divided by the total signal of the 11 fractions (0 - 10 - 50 and 60% sucrose) (mean +/- SD, * p<0.05, two-tailed P value n=3).

Supplementary Figure: Characterization of HEK293T clones stably expressing APP^{WT}mCherry and APP^{K28A}mCherry. **A, B:** MSD assay for secreted A β 40 and A β 42 respectively. No A β 40 and 42 were detected in the HEK293T untransfected control clones. One-way ANOVA Tukey's multiple comparisons (n=3, mean $\pm$ standard error); **C:** Western blot analysis of mcherry expression levels of clones stably expressing APPwt-mCherry and APPK28A-mCherry were detected with an anti-mCherry antibody. **D:** Expression levels of APPmCherry were quantified using ImageJ. Expression levels relative to actin were normalized to the APPmCherry level of each clones. Statistics: two-way ANOVA (n=3, mean $\pm$ standard error). ****p<0.0001***p<0.001** p<0.01

Supplementary Table: Heatmap showing APP/A β peptides detected using LC-ESI-MS for APP^{WT} and APP^{K28A} treated (+) and untreated (-) with cholesterol. Peptide numbering refers to the A β sequence, where negative numbers indicate the number of positions N-terminally of the BACE1 cleavage site. The intensity (logarithmic scale) is the peak area normalised to total protein content in the respective sample.

References

1. Duyckaerts C, Delatour B, Potier MC. Classification and basic pathology of Alzheimer disease. *Acta Neuropathol.* 2009;118(1):5-36.
2. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Mol Med.* 2016;8(6):595-608.
3. De Strooper B, Annaert W. Novel research horizons for presenilins and gamma-secretases in cell biology and disease. *Annu Rev Cell Dev Biol.* 2010;26:235-60.
4. Shobab LA, Hsiung GY, Feldman HH. Cholesterol in Alzheimer's disease. *Lancet Neurol.* 2005;4(12):841-52.
5. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. *Proc Natl Acad Sci U S A.* 1993;90(5):1977-81.
6. Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, et al. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. *Proc Natl Acad Sci U S A.* 2004;101(7):2070-5.
7. Di Paolo G, Kim TW. Linking lipids to Alzheimer's disease: cholesterol and beyond. *Nat Rev Neurosci.* 2011;12(5):284-96.
8. Lazar AN, Bich C, Panchal M, Desbenoit N, Petit VW, Touboul D, et al. Time-of-flight secondary ion mass spectrometry (TOF-SIMS) imaging reveals cholesterol overload in the cerebral cortex of Alzheimer disease patients. *Acta Neuropathol.* 2012;125(1):133-44.
9. Panchal M, Loeper J, Cossec JC, Perruchini C, Lazar A, Pompon D, et al. Enrichment of cholesterol in microdissected Alzheimer's disease senile plaques as assessed by mass spectrometry. *J Lipid Res.* 2010;51(3):598-605.
10. Xiong H, Callaghan D, Jones A, Walker DG, Lue LF, Beach TG, et al. Cholesterol retention in Alzheimer's brain is responsible for high beta- and gamma-secretase activities and A beta production. *Neurobiol Dis.* 2008;29(3):422-37.
11. Cordy JM, Hussain I, Dingwall C, Hooper NM, Turner AJ. Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. *Proc Natl Acad Sci U S A.* 2003;100(20):11735-40.
12. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. *Proc Natl Acad Sci U S A.* 1998;95(11):6460-4.
13. Cossec JC, Marquer C, Panchal M, Lazar AN, Duyckaerts C, Potier MC. Cholesterol changes in Alzheimer's disease: Methods of analysis and impact on the formation of enlarged endosomes. *Biochim Biophys Acta.* 2010.
14. Cossec JC, Simon A, Marquer C, Moldrich RX, Leterrier C, Rossier J, et al. Clathrin-dependent APP endocytosis and A beta secretion are highly sensitive to the level of plasma membrane cholesterol. *Biochim Biophys Acta.* 2010;1801(8):846-52.
15. Marquer C, Devaues V, Cossec JC, Liot G, Lecart S, Saudou F, et al. Local cholesterol increase triggers amyloid precursor protein-Bace1 clustering in lipid rafts and rapid endocytosis. *FASEB J.* 2011;25(4):1295-305.
16. Marquer C, Laine J, Dauphinot L, Hanbouch L, Lemercier-Neuillet C, Pierrot N, et al. Increasing membrane cholesterol of neurons in culture recapitulates Alzheimer's disease early phenotypes. *Molecular neurodegeneration.* 2014;9:60.
17. Grimm MO, Grimm HS, Tomic I, Beyreuther K, Hartmann T, Bergmann C. Independent inhibition of Alzheimer disease beta- and gamma-secretase cleavage by lowered cholesterol levels. *J Biol Chem.* 2008;283(17):11302-11.
18. Osenkowski P, Ye W, Wang R, Wolfe MS, Selkoe DJ. Direct and potent regulation of gamma-secretase by its lipid microenvironment. *J Biol Chem.* 2008;283(33):22529-40.
19. Pierrot N, Tyteca D, D'Auria L, Dewachter I, Gailly P, Hendrickx A, et al. Amyloid precursor protein controls cholesterol turnover needed for neuronal activity. *EMBO Mol Med.* 2013;5(4):608-25.

20. Di Scala C, Chahinian H, Yahi N, Garay N, Fantini J. Interaction of Alzheimer's beta-amyloid peptides with cholesterol: mechanistic insights into amyloid pore formation. *Biochemistry*. 2014;53(28):4489-502.
21. Fantini J, Yahi N, Garay N. Cholesterol accelerates the binding of Alzheimer's beta-amyloid peptide to ganglioside GM1 through a universal hydrogen-bond-dependent sterol tuning of glycolipid conformation. *Front Physiol*. 2013;4:120.
22. Barrett PJ, Song Y, Van Horn WD, Hustedt EJ, Schafer JM, Hadziselimovic A, et al. The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. *Science*. 2012;336(6085):1168-71.
23. Beel AJ, Mobley CK, Kim HJ, Tian F, Hadziselimovic A, Jap B, et al. Structural studies of the transmembrane C-terminal domain of the amyloid precursor protein (APP): does APP function as a cholesterol sensor? *Biochemistry*. 2008;47(36):9428-46.
24. Beel AJ, Sakakura M, Barrett PJ, Sanders CR. Direct binding of cholesterol to the amyloid precursor protein: An important interaction in lipid-Alzheimer's disease relationships? *Biochim Biophys Acta*. 2012.
25. Nierzwicki L, Czub J. Specific Binding of Cholesterol to the Amyloid Precursor Protein: Structure of the Complex and Driving Forces Characterized in Molecular Detail. *J Phys Chem Lett*. 2015;6(5):784-90.
26. Moore BD, Martin J, de Mena L, Sanchez J, Cruz PE, Ceballos-Diaz C, et al. Short Abeta peptides attenuate Abeta42 toxicity in vivo. *J Exp Med*. 2018;215(1):283-301.
27. Vandersteen A, Hubin E, Sarroukh R, De Baets G, Schymkowitz J, Rousseau F, et al. A comparative analysis of the aggregation behavior of amyloid-beta peptide variants. *FEBS Lett*. 2012;586(23):4088-93.
28. Portelius E, Tran AJ, Andreasson U, Persson R, Brinkmalm G, Zetterberg H, et al. Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. *J Proteome Res*. 2007;6(11):4433-9.
29. Brinkmalm G, Portelius E, Ohrfelt A, Mattsson N, Persson R, Gustavsson MK, et al. An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid beta and amyloid precursor protein in human and cat cerebrospinal fluid. *J Mass Spectrom*. 2012;47(5):591-603.
30. Gkanatsiou E, Portelius E, Toomey CE, Blennow K, Zetterberg H, Lashley T, et al. A distinct brain beta amyloid signature in cerebral amyloid angiopathy compared to Alzheimer's disease. *Neurosci Lett*. 2019;701:125-31.
31. Hartmann T, Bieger SC, Bruhl B, Tienari PJ, Ida N, Allsop D, et al. Distinct sites of intracellular production for Alzheimer's disease A beta40/42 amyloid peptides. *Nat Med*. 1997;3(9):1016-20.
32. Kienlen-Campard P, Tasiaux B, Van Hees J, Li M, Huyseune S, Sato T, et al. Amyloidogenic processing but not amyloid precursor protein (APP) intracellular C-terminal domain production requires a precisely oriented APP dimer assembled by transmembrane GXXXG motifs. *J Biol Chem*. 2008;283(12):7733-44.
33. Panahi A, Bandara A, Pantelopulos GA, Dominguez L, Straub JE. Specific Binding of Cholesterol to C99 Domain of Amyloid Precursor Protein Depends Critically on Charge State of Protein. *J Phys Chem Lett*. 2016;7(18):3535-41.
34. Bugiani O, Giaccone G, Rossi G, Mangieri M, Capobianco R, Morbin M, et al. Hereditary cerebral hemorrhage with amyloidosis associated with the E693K mutation of APP. *Arch Neurol*. 2010;67(8):987-95.
35. Miravalle L, Tokuda T, Chiarle R, Giaccone G, Bugiani O, Tagliavini F, et al. Substitutions at codon 22 of Alzheimer's abeta peptide induce diverse conformational changes and apoptotic effects in human cerebral endothelial cells. *J Biol Chem*. 2000;275(35):27110-6.
36. Nicastro MC, Spigolon D, Librizzi F, Moran O, Ortore MG, Bulone D, et al. Amyloid beta-peptide insertion in liposomes containing GM1-cholesterol domains. *Biophys Chem*. 2016;208:9-16.
37. Steck TL, Lange Y. Transverse distribution of plasma membrane bilayer cholesterol: Picking sides. *Traffic*. 2018;19(10):750-60.

38. Murate M, Kobayashi T. Revisiting transbilayer distribution of lipids in the plasma membrane. *Chem Phys Lipids*. 2016;194:58-71.
39. Rivel T, Ramseyer C, Yesylevskyy S. The asymmetry of plasma membranes and their cholesterol content influence the uptake of cisplatin. *Sci Rep*. 2019;9(1):5627.
40. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, et al. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. *Nat Neurosci*. 2001;4(9):887-93.
41. Ren Z, Schenk D, Basi GS, Shapiro IP. Amyloid beta-protein precursor juxtamembrane domain regulates specificity of gamma-secretase-dependent cleavages. *J Biol Chem*. 2007;282(48):35350-60.
42. Kukar TL, Ladd TB, Robertson P, Pintchovski SA, Moore B, Bann MA, et al. Lysine 624 of the amyloid precursor protein (APP) is a critical determinant of amyloid beta peptide length: support for a sequential model of gamma-secretase intramembrane proteolysis and regulation by the amyloid beta precursor protein (APP) juxtamembrane region. *J Biol Chem*. 2011;286(46):39804-12.
43. Tarus B, Straub JE, Thirumalai D. Structures and free-energy landscapes of the wild type and mutants of the Abeta(21-30) peptide are determined by an interplay between intrapeptide electrostatic and hydrophobic interactions. *J Mol Biol*. 2008;379(4):815-29.
44. Sambasivam D, Sivanesan S, Ashok BS, Rajadas J. Structural preferences of Abeta fragments in different micellar environments. *Neuropeptides*. 2011;45(6):369-76.
45. Shuaib S, Saini RK, Goyal D, Goyal B. Impact of K16A and K28A mutation on the structure and dynamics of amyloid-beta42 peptide in Alzheimer's disease: key insights from molecular dynamics simulations. *J Biomol Struct Dyn*. 2020;38(3):708-21.
46. Fluhrer R, Multhaup G, Schlicksupp A, Okochi M, Takeda M, Lammich S, et al. Identification of a beta-secretase activity, which truncates amyloid beta-peptide after its presenilin-dependent generation. *J Biol Chem*. 2003;278(8):5531-8.
47. Shi XP, Tugusheva K, Bruce JE, Lucka A, Wu GX, Chen-Dodson E, et al. Beta-secretase cleavage at amino acid residue 34 in the amyloid beta peptide is dependent upon gamma-secretase activity. *J Biol Chem*. 2003;278(23):21286-94.
48. Caillava C, Ranaldi S, Lauritzen I, Bauer C, Fareh J, Abraham JD, et al. Study on Abeta34 biology and detection in transgenic mice brains. *Neurobiol Aging*. 2014;35(7):1570-81.
49. Akerman SC, Hossain S, Shobo A, Zhong Y, Jourdain R, Hancock MA, et al. Neurodegenerative Disease-Related Proteins within the Epidermal Layer of the Human Skin. *J Alzheimers Dis*. 2019;69(2):463-78.
50. Kirabali T, Rigotti S, Siccoli A, Liebsch F, Shobo A, Hock C, et al. The amyloid-beta degradation intermediate Abeta34 is pericyte-associated and reduced in brain capillaries of patients with Alzheimer's disease. *Acta Neuropathol Commun*. 2019;7(1):194.
51. Liebsch F, Kulic L, Teunissen C, Shobo A, Ulku I, Engelschalt V, et al. Abeta34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression. *Nat Commun*. 2019;10(1):2240.
52. Hernandez-Guillamon M, Mawhirt S, Blais S, Montaner J, Neubert TA, Rostagno A, et al. Sequential Amyloid-beta Degradation by the Matrix Metalloproteases MMP-2 and MMP-9. *J Biol Chem*. 2015;290(24):15078-91.
53. Dawkins E, Small DH. Insights into the physiological function of the beta-amyloid precursor protein: beyond Alzheimer's disease. *J Neurochem*. 2014;129(5):756-69.
54. Wilhelm BG, Mandad S, Truckenbrodt S, Krohnert K, Schafer C, Rammner B, et al. Composition of isolated synaptic boutons reveals the amounts of vesicle trafficking proteins. *Science*. 2014;344(6187):1023-8.
55. Samant NP, Gupta GL. Novel therapeutic strategies for Alzheimer's disease targeting brain cholesterol homeostasis. *Eur J Neurosci*. 2020.
56. Hudry E, Van Dam D, Kulik W, De Deyn PP, Stet FS, Ahouansou O, et al. Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease. *Mol Ther*. 2010;18(1):44-53.

57. van der Kant R, Langness VF, Herrera CM, Williams DA, Fong LK, Leestemaker Y, et al. Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-beta in iPSC-Derived Alzheimer's Disease Neurons. *Cell Stem Cell*. 2019;24(3):363-75 e9.
58. Lopez-Gambero AJ, Sanjuan C, Serrano-Castro PJ, Suarez J, Rodriguez de Fonseca F. The Biomedical Uses of Inositols: A Nutraceutical Approach to Metabolic Dysfunction in Aging and Neurodegenerative Diseases. *Biomedicines*. 2020;8(9).
59. Sinha S, Du Z, Maiti P, Klarnar FG, Schrader T, Wang C, et al. Comparison of three amyloid assembly inhibitors: the sugar scyllo-inositol, the polyphenol epigallocatechin gallate, and the molecular tweezer CLR01. *ACS Chem Neurosci*. 2012;3(6):451-8.
60. Sinha S, Lopes DH, Bitan G. A key role for lysine residues in amyloid beta-protein folding, assembly, and toxicity. *ACS Chem Neurosci*. 2012;3(6):473-81.

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

Supplementary Figure

Supplementary Table